San Diego-dependent Viking Therapeutics marked alone as a serious competitor during the weight loss drug current market in February after revealing promising facts from the mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied being a weekly injection As well as in March the